1.57p-0.01 (-0.32%)22 Nov 2024, 15:33
Jump to:
Immupharma PLC Fundamentals
Company Name | Immupharma PLC | Last Updated | 2024-11-22 |
---|---|---|---|
Industry | Biotechnology | Sector | Healthcare |
Shares in Issue | 416.437 m | Market Cap | £6.52 m |
PE Ratio | 0.00 | Dividend per Share | 0 |
Dividend Yield | 0 | Dividend Cover | 0 |
EPS | -£0.01 | EPS Growth (%) | 0 |
PEG | 0 | DPS Growth (%) | 0 |
Debt Ratio | 0 | Debt Equity Ratio | 0 |
Asset Equity Ratio | 1.5096 | Cash Equity Ratio | 0.4030 |
Quick Ratio | 1.0450 | Current Ratio | 1.60 |
Price To Book Value | 2.4219 | ROCE | 0 |
Immupharma PLC Dividends
Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
---|
Immupharma PLC Company Financials
Assets | 2023 | 2022 | 2021 |
---|---|---|---|
Tangible Assets | £102,075.00 | £389,718.00 | £352,996.00 |
Intangible Assets | £447,571.00 | £473,892.00 | £477,553.00 |
Investments | £643,781.00 | £688,350.00 | £1.21 m |
Total Fixed Assets | £1.38 m | £1.64 m | £2.65 m |
Stocks | 0 | 0 | 0 |
Debtors | £451,546.00 | £649,401.00 | £373,253.00 |
Cash & Equivalents | £208,481.00 | £667,813.00 | £1.65 m |
Other Assets | £184,785.00 | £83,790.00 | £612,997.00 |
Total Assets | £2.72 m | £3.97 m | £6.00 m |
Liabilities | 2023 | 2022 | 2021 |
---|---|---|---|
Creditors within 1 year | £1.67 m | £1.45 m | £1.58 m |
Creditors after 1 year | 0 | 0 | 0 |
Other Liabilities | 0 | 0 | 0 |
Total Liabilities | £1.67 m | £1.45 m | £1.58 m |
Net assets | £1.06 m | £2.52 m | £4.41 m |
Equity | 2023 | 2022 | 2021 |
---|---|---|---|
Called up share capital | £29.81 m | £28.98 m | £28.50 m |
Share Premium | £29.32 m | £28.79 m | £27.24 m |
Profit / Loss | -£3.42 m | -£4.46 m | -£8.94 m |
Other Equity | £1.06 m | £2.52 m | £4.41 m |
Preference & Minorities | 0 | 0 | 0 |
Total Capital Employed | £1.06 m | £2.52 m | £4.41 m |
Ratios | 2023 | 2022 | 2021 |
---|---|---|---|
Debt Ratio | 0 | 0 | 0 |
Debt-to-Equity | 0 | 0 | 0 |
Assets / Equity | 1.5096 | 1.5096 | 1.5096 |
Cash / Equity | 0.4030 | 0.4030 | 0.4030 |
EPS | -£0.01 | -£0.01 | -£0.02 |
Cash Flow | 2023 | 2022 | 2021 |
---|---|---|---|
Cash from operating activities | -£1.36 m | -£2.35 m | -£4.83 m |
Cashflow before financing | -£642,311.00 | -£799,335.00 | -£4.13 m |
Increase in Cash | -£453,549.00 | -£876,759.00 | -£4.18 m |
Income | 2023 | 2022 | 2021 |
---|---|---|---|
Turnover | 0 | 0 | £118,350.00 |
Cost of sales | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 |
Operating Profit | -£3.06 m | -£3.03 m | -£6.59 m |
Pre-Tax profit | -£3.42 m | -£4.46 m | -£8.94 m |
Immupharma PLC Company Background
Sector | Healthcare |
---|---|
Activities | ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus, a life-threatening autoimmune disease. |
Latest Interim Date | 9 Sep 2024 |
Latest Fiscal Year End Date | 5 Jun 2024 |
Immupharma PLC Directors
Appointed | Name | Position |
---|---|---|
2021-07-30 | Dr. Franco Di Muzio | Non-Executive Director |
2006-03-31 | Mr. Douglas Gordon James Paterson | Non-Executive Director |
2024-03-19 | Mr. Timothy Paul McCarthy | Executive Director,Chairman and Chief Executive Officer |
2021-07-30 | Mr. Dimitri Dimitriou | Executive Director,Chief Executive Officer |
2021-05-24 | Dr. Robert Henri Zimmer | Executive Director,President and Chief Scientific Officer |
2016-05-05 | Mr. Richard Leonard Warr | Executive Director,Chairman |
2016-05-05 | Dr. Ajay Agrawal | Non-Executive Director |
2011-08-09 | Mr. Paddy Hugh Walker-Taylor FCA,MCT | Executive Director,Chief Financial Officer |
2006-03-31 | Mr. Anthony Johnson B.Pharm,MSc | Non-Executive Director |
2023-08-11 | Dr. Sanjeev Pandya | Non-Executive Director,Senior Independent Director |
2021-07-30 | Dr. Stephane Robert George Mery | Non-Executive Director |
2024-03-19 | Mr. Timothy Gary Franklin | Executive Director,Chief Operating Officer |
2024-04-19 | Ms. Lisa Baderoon | Non-Executive Director |
Immupharma PLC Contact Details
Company Name | ImmuPharma PLC |
---|---|
Address | One Bartholomew Close, London, EC1A 7BL |
Telephone | +44 2071524080 |
Website | https://www.immupharma.co.uk |
Immupharma PLC Advisors
Stockbroker | Bryan, Garnier & Co Limited |
---|---|
Phone | +44 2073322500 |
Nominated Adviser | Northland Capital Partners |
---|---|
Phone | +44 2038616625 |
Fax | +44 2076005975 |
Stockbroker | Northland Capital Partners |
---|---|
Phone | +44 2038616625 |
Fax | +44 2076005975 |
Registrar | Computershare Investor Services PLC |
---|---|
Phone | +44 3707020003 |
Fax | +44 3707036101 |
Auditor | Nexia Smith & Williamson |
---|---|
Phone | +44 2071314000 |
Fax | +44 2071314001 |
Solicitor | Bircham Dyson Bell |
---|---|
Phone | +44 2072277000 |
Fax | +44 2072223480 |
Bank | Royal Bank of Scotland PLC |
---|
Auditor | Nexia Smith & Williamson Audit Limited |
---|
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
Company | Price | % Chg |
---|---|---|
Games Workshop Group PLC | 13,730.00 | 17.25 |
Clarkson PLC | 3,935.00 | 9.31 |
Ithaca Energy PLC | 115.60 | 6.06 |
Diploma PLC | 4,466.00 | 5.78 |
Puretech Health PLC | 171.20 | 5.68 |
Itv PLC | 65.50 | 5.56 |
Fallers
Company | Price | % Chg |
---|---|---|
Cmc Markets PLC | 264.00 | -8.49 |
Close Brothers Group PLC | 200.40 | -6.53 |
W.A.G Payment Solutions PLC | 81.60 | -4.00 |
Investec PLC | 593.50 | -2.94 |
Goodwin PLC | 6,600.00 | -2.94 |
Fidelity China Special Situations PLC | 205.50 | -2.84 |
Risers/fallers data from previous trading day.